EcoR1 Capital TCRX Position
Exited3-Fund ConvergenceEcoR1 Capital exited their position in TScan Therapeutics, Inc. (TCRX) in Q2 2025, after holding the stock for 9 quarters.
The position was first reported in Q2 2023 and has been tracked across 9 quarterly 13F filings.
TCRX is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Full company profile →Short Interest
4.0%
3.2 days to cover
EcoR1 Capital TCRX Position History
Frequently Asked Questions
Does EcoR1 Capital own TCRX?
No. EcoR1 Capital exited their position in TScan Therapeutics, Inc. (TCRX) in Q2 2025. They previously held the stock for 9 quarters.
How many hedge funds own TCRX?
3 specialist biotech hedge funds currently hold TCRX, including BVF Partners, Baker Bros. Advisors, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy TCRX?
EcoR1 Capital's position in TCRX was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's TCRX position increasing or decreasing?
EcoR1 Capital completely exited their TCRX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TCRXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →